Pada pertengahan 2006, dacarbazine biasa digunakan sebagai agen tunggal dalam pengobatan [[melanoma]] [[metastasis]],<ref>{{cite journal|last1=Serrone|first1=L|last2=Zeuli|first2=M|last3=Sega|first3=FM|last4=Cognetti|first4=F|title=Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.|journal=Journal of experimental & clinical cancer research : CR|date=March 2000|volume=19|issue=1|pages=21–34|pmid=10840932}}</ref><ref>{{cite journal|last1=Bhatia|first1=S|last2=Tykodi|first2=SS|last3=Thompson|first3=JA|title=Treatment of metastatic melanoma: an overview.|journal=Oncology (Williston Park, N.Y.)|date=May 2009|volume=23|issue=6|pages=488–96|pmid=19544689|pmc=2737459}}</ref> dan sebagai bagian dari rejimen kemoterapi [[ABVD]] untuk mengobati [[limfoma Hodgkin]],<ref>{{cite journal|last1=Rueda Domínguez|first1=A|last2=Márquez|first2=A|last3=Gumá|first3=J|last4=Llanos|first4=M|last5=Herrero|first5=J|last6=de Las Nieves|first6=MA|last7=Miramón|first7=J|last8=Alba|first8=E|title=Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.|journal=Annals of Oncology|date=December 2004|volume=15|issue=12|pages=1798–804|pmid=15550585|doi=10.1093/annonc/mdh465}}</ref> dan dalam rejimen MAID untuk sarkoma .<ref>{{cite journal|last1=Elias|first1=A|last2=Ryan|first2=L|last3=Aisner|first3=J|last4=Antman|first4=KH|title=Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.|journal=Seminars in oncology|date=April 1990|volume=17|issue=2 Suppl 4|pages=41–9|pmid=2110385}}</ref><ref>{{cite journal|last1=Pearl|first1=ML|last2=Inagami|first2=M|last3=McCauley|first3=DL|last4=Valea|first4=FA|last5=Chalas|first5=E|last6=Fischer|first6=M|title=Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.|journal=International journal of gynecological cancer : official journal of the International Gynecological Cancer Society|date=2001|volume=12|issue=6|pages=745–8|pmid=12445253|doi=10.1046/j.1525-1438.2002.01139.x}}</ref> Dacarbazine terbukti sama manjurnya dengan procarbazine dalam percobaan Jerman untuk limfoma Hodgkin pediatrik, tanpa efek teratogenik. [Rujukan?] Jadi COPDAC telah menggantikan rezim COPP sebelumnya pada anak-anak untuk TG2 & 3 setelah OEPA.<ref>{{cite journal|last1=Mauz-Körholz|first1=C|last2=Hasenclever|first2=D|last3=Dörffel|first3=W|last4=Ruschke|first4=K|last5=Pelz|first5=T|last6=Voigt|first6=A|last7=Stiefel|first7=M|last8=Winkler|first8=M|last9=Vilser|first9=C|last10=Dieckmann|first10=K|last11=Karlén|first11=J|last12=Bergsträsser|first12=E|last13=Fosså|first13=A|last14=Mann|first14=G|last15=Hummel|first15=M|last16=Klapper|first16=W|last17=Stein|first17=H|last18=Vordermark|first18=D|last19=Kluge|first19=R|last20=Körholz|first20=D|title=Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.|journal=Journal of clinical oncology : official journal of the American Society of Clinical Oncology|date=10 August 2010|volume=28|issue=23|pages=3680–6|pmid=20625128|url=http://jco.ascopubs.org/content/28/23/3680.full|doi=10.1200/jco.2009.26.9381}}</ref>
